Adams, A.C., Halstead, C.A., Hansen, B.C., Irizarry, A.R., Martin, J.A., Myers, S.R., Reynolds, V.L., Smith, H.W., Wroblewski, V.J., et al., 2013. LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys. PloS one 8:e65763.
Adams, A.C., Yang, C., Coskun, T., Cheng, C.C., Gimeno, R.E., Luo, Y., Kharitonenkov, A., 2012. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab 2:31- 7.
An, S.Y., Lee, M.S., Yi, S.A., Ha, E.S., Han, S.J., Kim, H.J., Kim, D.J., Lee, K.W., 2012. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract 96:196-203.
Angelin, B., Larsson, T.E., Rudling, M., 2012. Circulating Fibroblast Growth Factors as Metabolic Regulators-A Critical Appraisal. Cell Metab 16:693-705.
Arici, M., Walls, J., 2001. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C- reactive protein the missing link? Kidney Int 59:407-14.
Ayabe, M., Yahiro, T., Yoshioka, M., Higuchi, H., Higaki, Y., Tanaka, H., 2009. Objectively measured age-related changes in the intensity distribution of daily physical activity in adults. J Phys Act Health 6:419-25.
Bookout, A.L., de Groot, M.H., Owen, B.M., Lee, S., Gautron, L., Lawrence, H.L., Ding, X., Elmquist, J.K., Takahashi, J.S., et al., 2013. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 19:1147-52.
Brahma, M.K., Adam, R.C., Pollak, N.M., Jaeger, D., Zierler, K.A., Pocher, N., Schreiber, R., Romauch, M., Moustafa, T., et al., 2014. Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis. J Lipid Res 55:2229-41.
Bramwell, J.C., Hill, A.V., 1922. Velocity of transmission of the pulse-wave and elasticity of the arteries. Lancet 199:891-92.
Chavez, A.O., Molina-Carrion, M., Abdul-Ghani, M.A., Folli, F., Defronzo, R.A., Tripathy, D., 2009. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32:1542-6.
Chen, C., Cheung, B.M., Tso, A.W., Wang, Y., Law, L.S., Ong, K.L., Wat, N.M., Xu, A., Lam, K.S., 2011. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 34:2113-5.
Cheng, J., Su, X., Qiao, L., Zhai, C., Chen, W., 2018. Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris. Biosci Rep 38.
Chow, W.S., Xu, A., Woo, Y.C., Tso, A.W., Cheung, S.C., Fong, C.H., Tse, H.F., Chau, M.T., Cheung, B.M., et al., 2013. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol 33:2454-9.
Coskun, T., Bina, H.A., Schneider, M.A., Dunbar, J.D., Hu, C.C., Chen, Y., Moller, D.E., Kharitonenkov, A., 2008. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018-27.
Cuevas-Ramos, D., Almeda-Valdes, P., Gomez-Perez, F.J., Meza-Arana, C.E., Cruz-Bautista, I., Arellano-Campos, O., Navarrete-Lopez, M., Aguilar-Salinas, C.A., 2010. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. Eur J Endocrinol 163:469-77.
Diaz-Delfin, J., Hondares, E., Iglesias, R., Giralt, M., Caelles, C., Villarroya, F., 2012. TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 153:4238-45.
Ding, X., Boney-Montoya, J., Owen, B.M., Bookout, A.L., Coate, K.C., Mangelsdorf, D.J., Kliewer, S.A., 2012. βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 16:387-93.
Domouzoglou, E.M., Naka, K.K., Vlahos, A.P., Papafaklis, M.I., Michalis, L.K., Tsatsoulis, A., Maratos-Flier, E., 2015. Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21. Am J Physiol Heart Circ Physiol 309:H1029-38.
Dong, K., Li, H., Zhang, M., Jiang, S., Chen, S., Zhou, J., Dai, Z., Fang, Q., Jia, W., 2015. Endoplasmic reticulum stress induces up-regulation of hepatic beta-Klotho expression through ATF4 signaling pathway. Biochem Biophys Res Commun 459:300-05.
Douris, N., Stevanovic, D.M., Fisher, F.M., Cisu, T.I., Chee, M.J., Nguyen, N.L., Zarebidaki, E., Adams, A.C., Kharitonenkov, A., et al., 2015. Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice. Endocrinology 156:2470-81.
Fisher, F.M., Chui, P.C., Antonellis, P.J., Bina, H.A., Kharitonenkov, A., Flier, J.S., Maratos-Flier, E., 2010. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59:2781-9.
Fisher, F.M., Maratos-Flier, E., 2016. Understanding the Physiology of FGF21. Annu Rev Physiol 78:223-41.
Foster, M.C., Hwang, S.J., Porter, S.A., Massaro, J.M., Hoffmann, U., Fox, C.S., 2011. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension (Dallas, Tex. : 1979) 58:784-90.
Fujii, N., Uta, S., Kobayashi, M., Sato, T., Okita, N., Higami, Y., 2019. Impact of aging and caloric restriction on fibroblast growth factor 21 signaling in rat white adipose tissue. Exp Gerontol 118:55- 64.
Furuhashi, M., Matsumoto, M., Murase, T., Nakamura, T., Higashiura, Y., Koyama, M., Tanaka, M., Moniwa, N., Ohnishi, H., et al., 2018. Independent links between plasma xanthine oxidoreductase activity and levels of adipokines. J Diabetes Investig.
Gaich, G., Chien, J.Y., Fu, H., Glass, L.C., Deeg, M.A., Holland, W.L., Kharitonenkov, A., Bumol, T., Schilske, H.K., et al., 2013. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18:333-40.
Gallego-Escuredo, J.M., Gómez-Ambrosi, J., Catalan, V., Domingo, P., Giralt, M., Frühbeck, G., Villarroya, F., 2015. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. International Journal of Obesity 39:121-29.
Gariani, K., Drifte, G., Dunn-Siegrist, I., Pugin, J., Jornayvaz, F.R., 2013. Increased FGF21 plasma levels in humans with sepsis and SIRS. Endocr Connect 2:146-53.
Ge, X., Chen, C., Hui, X., Wang, Y., Lam, K.S., Xu, A., 2011. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J Biol Chem 286:34533-41.
Geng, L., Liao, B., Jin, L., Huang, Z., Triggle, C.R., Ding, H., Zhang, J., Huang, Y., Lin, Z., et al., 2019. Exercise Alleviates Obesity-Induced Metabolic Dysfunction via Enhancing FGF21 Sensitivity in Adipose Tissues. Cell Rep 26:2738-52.e4.
Gomez-Samano, M.A., Grajales-Gomez, M., Zuarth-Vazquez, J.M., Navarro-Flores, M.F., Martinez- Saavedra, M., Juarez-Leon, O.A., Morales-Garcia, M.G., Enriquez-Estrada, V.M., Gomez-Perez, F.J., et al., 2017. Fibroblast growth factor 21 and its novel association with oxidative stress. Redox Biol 11:335-41.
Hale, C., Chen, M.M., Stanislaus, S., Chinookoswong, N., Hager, T., Wang, M., Veniant, M.M., Xu, J., 2012. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 153:69-80.
Han, S.H., Choi, S.H., Cho, B.J., Lee, Y., Lim, S., Park, Y.J., Moon, M.K., Lee, H.K., Kang, S.W., et al., 2010. Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism 59:1656-62.
Hanks, L.J., Gutierrez, O.M., Bamman, M.M., Ashraf, A., McCormick, K.L., Casazza, K., 2015. Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals. J Clin Transl Endocrinol 2:77-82.
Hidalgo-Santamaria, M., Bes-Rastrollo, M., Martinez-Gonzalez, M.A., Moreno-Galarraga, L., Ruiz- Canela, M., Fernandez-Montero, A., 2018. Physical Activity Intensity and Cardiovascular Disease Prevention—From the Seguimiento Universidad de Navarra Study. Am J Cardiol 122:1871-78.
Hikihara, Y., Tanaka, S., Ohkawara, K., Ishikawa-Takata, K., Tabata, I., 2012. Validation and comparison of 3 accelerometers for measuring physical activity intensity during nonlocomotive activities and locomotive movements. J Phys Act Health 9:935-43.
Hindricks, J., Ebert, T., Bachmann, A., Kralisch, S., Lossner, U., Kratzsch, J., Stolzenburg, J.U., Dietel, A., Beige, J., et al., 2014. Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clinical Endocrinol 80:918-24.
Hondares, E., Iglesias, R., Giralt, A., Gonzalez, F.J., Giralt, M., Mampel, T., Villarroya, F., 2011. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem 286:12983-90.
Horio, M., Imai, E., Yasuda, Y., Watanabe, T., Matsuo, S., 2013a. GFR Estimation Using Standardized Serum Cystatin C in Japan. Am J Kidney Dis 61:197-203.
Horio, M., Imai, E., Yasuda, Y., Watanabe, T., Matsuo, S., 2013b. Performance of GFR equations in Japanese subjects. Clin Exp Nephrol 17:352-58.
Hsuchou, H., Pan, W., Kastin, A.J., 2007. The fasting polypeptide FGF21 can enter brain from blood. Peptides 28:2382-6.
Huang, C.J., McAllister, M.J., Slusher, A.L., Webb, H.E., Mock, J.T., Acevedo, E.O., 2015. Obesity- Related Oxidative Stress: the Impact of Physical Activity and Diet Manipulation. Sports Med Open 1:32.
Iglesias, P., Selgas, R., Romero, S., Diez, J.J., 2012. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol 167:301-9.
Itoh, N., Ornitz, D.M., 2011. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 149:121-30.
Jeanson, Y., Ribas, F., Galinier, A., Arnaud, E., Ducos, M., Andre, M., Chenouard, V., Villarroya, F., Casteilla, L., et al., 2016. Lactate induces FGF21 expression in adipocytes through a p38-MAPK pathway. Biochem J 473:685-92.
Jiang, S., Yan, C., Fang, Q.C., Shao, M.L., Zhang, Y.L., Liu, Y., Deng, Y.P., Shan, B., Liu, J.Q., et al., 2014. Fibroblast growth factor 21 is regulated by the IRE1alpha-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J Biol Chem 289:29751-65.
Kasapis, C., Thompson, P.D., 2005. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol 45:1563-9.
Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., Sandusky, G.E., Hammond, L.J., Moyers, J.S., et al., 2005. FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627-35.
Kim, A.M., Somayaji, V.R., Dong, J.Q., Rolph, T.P., Weng, Y., Chabot, J.R., Gropp, K.E., Talukdar, S., Calle, R.A., 2017. Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates. Diabetes Obes Metab 19:1762-72.
Kim, K.H., Lee, M.S., 2015. FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs. J Endocrinol 226:R1-16.
Kim, S.H., Kim, K.H., Kim, H.K., Kim, M.J., Back, S.H., Konishi, M., Itoh, N., Lee, M.S., 2015. Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia 58:809-18.
Kohara, M., Masuda, T., Shiizaki, K., Akimoto, T., Watanabe, Y., Honma, S., Sekiguchi, C., Miyazawa, Y., Kusano, E., et al., 2017. Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PloS one 12:e0178971.
Kokkinos, J., Tang, S., Rye, K.A., Ong, K.L., 2017. The role of fibroblast growth factor 21 in atherosclerosis. Atherosclerosis 257:259-65.
Kosaki, K., Kamijo-Ikemori, A., Sugaya, T., Tanahashi, K., Kumagai, H., Sawano, Y., Akazawa, N., Ra, S.G., Kimura, K., et al., 2017. Relationship between exercise capacity and urinary liver-type fatty acid-binding protein in middle-aged and older individuals. Clin Exp Nephrol 21:810-17.
Krievina, G., Tretjakovs, P., Skuja, I., Silina, V., Keisa, L., Krievina, D., Bahs, G., 2016. Ectopic Adipose Tissue Storage in the Left and the Right Renal Sinus is Asymmetric and Associated With Serum Kidney Injury Molecule-1 and Fibroblast Growth Factor-21 Levels Increase. EBioMedicine 13:274-83.
Kruse, R., Vienberg, S.G., Vind, B.F., Andersen, B., Højlund, K., 2017. Effects of insulin and exercise training on FGF21, its receptors and target genes in obesity and type 2 diabetes. Diabetologia 60:2042- 51.
Kubota, Y., Iso, H., Yamagishi, K., Sawada, N., Tsugane, S., 2017. Daily Total Physical Activity and Incident Cardiovascular Disease in Japanese Men and Women: Japan Public Health Center-Based Prospective Study. Circulation 135:1471-73.
Kumahara, H., Schutz, Y., Ayabe, M., Yoshioka, M., Yoshitake, Y., Shindo, M., Ishii, K., Tanaka, H., 2004. The use of uniaxial accelerometry for the assessment of physical-activity-related energy expenditure: a validation study against whole-body indirect calorimetry. Br J Nutr 91:235-43.
Lakhani, I., Gong, M., Wong, W.T., Bazoukis, G., Lampropoulos, K., Wong, S.H., Wu, W.K.K., Wong, M.C.S., Ong, K.L., et al., 2018. Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysis. Metabolism 83:11-17.
Lee, C.H., Hui, E.Y., Woo, Y.C., Yeung, C.Y., Chow, W.S., Yuen, M.M., Fong, C.H., Xu, A., Lam, K.S., 2015. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. J Clin Endocrinol Metab 100:1368-75.
Lee, C.H., Woo, Y.C., Chow, W.S., Cheung, C.Y.Y., Fong, C.H.Y., Yuen, M.M.A., Xu, A., Tse, H.F.,
Lam, K.S.L., 2017. Role of circulating fibroblast growth factor 21 measurement in primary prevention of coronary heart disease among Chinese patients with type 2 diabetes mellitus. J Am Heart Assoc 6.
Li, F., Tang, C., Dong, Z., 2016. Therapeutic potential of FGF21 in cardiorenal syndrome. Int J Cardiol 214:70-1.
Li, H., Fang, Q., Gao, F., Fan, J., Zhou, J., Wang, X., Zhang, H., Pan, X., Bao, Y., et al., 2010. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 53:934-40.
Li, X., Fan, X., Ren, F., Zhang, Y., Shen, C., Ren, G., Sun, J., Zhang, N., Wang, W., et al., 2011. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res Clin Pract 93:10-6.
Liang, Q., Zhong, L., Zhang, J., Wang, Y., Bornstein, S.R., Triggle, C.R., Ding, H., Lam, K.S., Xu, A., 2014. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 63:4064-75.
Lin, Z., Wu, Z., Yin, X., Liu, Y., Yan, X., Lin, S., Xiao, J., Wang, X., Feng, W., et al., 2010. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PloS one 5:e15534.
Lin, Z., Zhou, Z., Liu, Y., Gong, Q., Yan, X., Xiao, J., Wang, X., Lin, S., Feng, W., et al., 2011. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PloS one 6:e18398.
Liu, J.J., Foo, J.P., Liu, S., Lim, S.C., 2015. The role of fibroblast growth factor 21 in diabetes and its complications: A review from clinical perspective. Diabetes Res Clin Pract 108:382-9.
Liu, X., Zhang, P., Martin, R.C., Cui, G., Wang, G., Tan, Y., Cai, L., Lv, G., Li, Y., 2016. Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice. Am J Cancer Res 6:1011-25.
Lu, Y., Liu, J.H., Zhang, L.K., Du, J., Zeng, X.J., Hao, G., Huang, J., Zhao, D.H., Wang, G.Z., et al., 2010. Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells. Chin Med J (Engl) 123:3417-21.
Mai, K., Bobbert, T., Groth, C., Assmann, A., Meinus, S., Kraatz, J., Andres, J., Arafat, A.M., Pfeiffer, A.F., et al., 2010. Physiological modulation of circulating FGF21: relevance of free fatty acids and insulin. Am J Physiol Endocrinol Metab 299:E126-30.
Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, Y., Yokoyama, H., et al., 2009. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982-92.
Micanovic, R., Raches, D.W., Dunbar, J.D., Driver, D.A., Bina, H.A., Dickinson, C.D., Kharitonenkov, A., 2009. Different roles of N- and C- termini in the functional activity of FGF21. J Cell Physiol 219:227-34.
Miyake, M., Nomura, A., Ogura, A., Takehana, K., Kitahara, Y., Takahara, K., Tsugawa, K., Miyamoto, C., Miura, N., et al., 2016. Skeletal muscle-specific eukaryotic translation initiation factor 2alpha phosphorylation controls amino acid metabolism and fibroblast growth factor 21-mediated non-cell- autonomous energy metabolism. Faseb J 30:798-812.
Mraz, M., Bartlova, M., Lacinova, Z., Michalsky, D., Kasalicky, M., Haluzikova, D., Matoulek, M., Dostalova, I., Humenanska, V., et al., 2009. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol 71:369-75.
Murakami, H., Kawakami, R., Nakae, S., Nakata, Y., Ishikawa-Takata, K., Tanaka, S., Miyachi, M., 2016. Accuracy of wearable devices for estimating total energy expenditure: Comparison with metabolic chamber and doubly labeled water method. JAMA Intern Med 176:702-03.
Nilsson, A., Bergens, O., Kadi, F., 2018. Physical activity alters inflammation in older adults by different intensity levels. Med Sci Sports Exerc 50:1502-07.
Nygaard, E.B., Moller, C.L., Kievit, P., Grove, K.L., Andersen, B., 2014. Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (Macaca mulatta). Int J Obes (Lond) 38:183-91.
Ohkawara, K., Oshima, Y., Hikihara, Y., Ishikawa-Takata, K., Tabata, I., Tanaka, S., 2011. Real-time estimation of daily physical activity intensity by a triaxial accelerometer and a gravity-removal classification algorithm. Br J Nutr 105:1681-91.
Ong, K.L., Januszewski, A.S., O'Connell, R., Jenkins, A.J., Xu, A., Sullivan, D.R., Barter, P.J., Hung, W.T., Scott, R.S., et al., 2015. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia 58:464-73.
Oshima, Y., Kawaguchi, K., Tanaka, S., Ohkawara, K., Hikihara, Y., Ishikawa-Takata, K., Tabata, I., 2010. Classifying household and locomotive activities using a triaxial accelerometer. Gait Posture 31:370-4.
Owen, B.M., Bookout, A.L., Ding, X., Lin, V.Y., Atkin, S.D., Gautron, L., Kliewer, S.A., Mangelsdorf, D.J., 2013. FGF21 contributes to neuroendocrine control of female reproduction. Nat Med 19:1153-6.
Owen, B.M., Ding, X., Morgan, D.A., Coate, K.C., Bookout, A.L., Rahmouni, K., Kliewer, S.A., Mangelsdorf, D.J., 2014. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab 20:670-7.
Patel, R., Bookout, A.L., Magomedova, L., Owen, B.M., Consiglio, G.P., Shimizu, M., Zhang, Y., Mangelsdorf, D.J., Kliewer, S.A., et al., 2015. Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop. Mol Endocrinol 29:213-23.
Patel, V., Adya, R., Chen, J., Ramanjaneya, M., Bari, M.F., Bhudia, S.K., Hillhouse, E.W., Tan, B.K., Randeva, H.S., 2014. Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PloS one 9:e87102.
Perissiou, M., Bailey, T.G., Windsor, M., Nam, M.C.Y., Greaves, K., Leicht, A.S., Golledge, J., Askew, C.D., 2018. Effects of exercise intensity and cardiorespiratory fitness on the acute response of arterial stiffness to exercise in older adults. Eur J Appl Physiol 118:1673-88.
Planavila, A., Redondo-Angulo, I., Ribas, F., Garrabou, G., Casademont, J., Giralt, M., Villarroya, F., 2015. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res 106:19-31.
Planavila, A., Redondo, I., Hondares, E., Vinciguerra, M., Munts, C., Iglesias, R., Gabrielli, L.A., Sitges, M., Giralt, M., et al., 2013. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 4:2019.
Prince, S.A., Adamo, K.B., Hamel, M.E., Hardt, J., Connor Gorber, S., Tremblay, M., 2008. A comparison of direct versus self-report measures for assessing physical activity in adults: a systematic review. Int J Behav Nutr Phys Act 5:56.
Roth, G.A., Forouzanfar, M.H., Moran, A.E., Barber, R., Nguyen, G., Feigin, V.L., Naghavi, M., Mensah, G.A., Murray, C.J., 2015. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med 372:1333-41.
Rusli, F., Deelen, J., Andriyani, E., Boekschoten, M.V., Lute, C., van den Akker, E.B., Muller, M., Beekman, M., Steegenga, W.T., 2016. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice. Sci Rep 6:30484.
Sa-Nguanmoo, P., Chattipakorn, N., Chattipakorn, S.C., 2016. Potential roles of fibroblast growth factor 21 in the brain. Metab Brain Dis 31:239-48.
Salminen, A., Kaarniranta, K., Kauppinen, A., 2017. Regulation of longevity by FGF21: Interaction between energy metabolism and stress responses. Ageing Res Rev 37:79-93.
Samms, R.J., Cheng, C.C., Kharitonenkov, A., Gimeno, R.E., Adams, A.C., 2016. Overexpression of beta-Klotho in adipose tissue sensitizes male mice to endogenous FGF21 and provides protection from diet-induced obesity. Endocrinology 157:1467-80.
Sarruf, D.A., Thaler, J.P., Morton, G.J., German, J., Fischer, J.D., Ogimoto, K., Schwartz, M.W., 2010. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59:1817-24.
Schaap, F.G., Kremer, A.E., Lamers, W.H., Jansen, P.L., Gaemers, I.C., 2013. Fibroblast growth factor 21 is induced by endoplasmic reticulum stress. Biochimie 95:692-9.
Sequí-Domínguez, I., Cavero-Redondo, I., Álvarez-Bueno, C., Pozuelo-Carrascosa, D.P., Nuñez de Arenas-Arroyo, S., Martínez-Vizcaíno, V., 2020. Accuracy of pulse wave velocity predicting cardiovascular and all-cause mortality. A systematic review and meta-analysis. J Clin Med 9:2080.
Shen, Y., Zhang, X., Xu, Y., Xiong, Q., Lu, Z., Ma, X., Bao, Y., Jia, W., 2018. Serum FGF21 is associated with future cardiovascular events in patients with coronary artery disease. Cardiology 139:212-18.
Shepherd, P.R., Kahn, B.B., 1999. Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. N Engl J Med 341:248-57.
Singhal, G., Fisher, F.M., Chee, M.J., Tan, T.G., El Ouaamari, A., Adams, A.C., Najarian, R., Kulkarni, R.N., Benoist, C., et al., 2016. Fibroblast growth factor 21 (FGF21) protects against high fat diet induced inflammation and islet hyperplasia in pancreas. PloS one 11:e0148252.
So, W.Y., Cheng, Q., Chen, L., Evans-Molina, C., Xu, A., Lam, K.S., Leung, P.S., 2013. High glucose represses beta-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor gamma signaling. Diabetes 62:3751- 9.
Stein, S., Bachmann, A., Lossner, U., Kratzsch, J., Bluher, M., Stumvoll, M., Fasshauer, M., 2009. Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 32:126-8.
Sugawara, J., Hayashi, K., Yokoi, T., Cortez-Cooper, M.Y., DeVan, A.E., Anton, M.A., Tanaka, H., 2005. Brachial-ankle pulse wave velocity: an index of central arterial stiffness? J Hum Hypertens 19:401-6.
Tan, B.K., Hallschmid, M., Adya, R., Kern, W., Lehnert, H., Randeva, H.S., 2011. Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity. Diabetes 60:2758-62.
Taniguchi, H., Tanisawa, K., Sun, X., Cao, Z.B., Oshima, S., Ise, R., Sakamoto, S., Higuchi, M., 2014. Cardiorespiratory fitness and visceral fat are key determinants of serum fibroblast growth factor 21 concentration in Japanese men. J Clin Endocrinol Metab 99:E1877-84.
Taniguchi, H., Tanisawa, K., Sun, X., Kubo, T., Higuchi, M., 2016. Endurance exercise reduces hepatic fat content and serum fibroblast growth factor 21 levels in elderly men. J Clin Endocrinol Metab 101:191-8.
Turner, T., Chen, X., Zahner, M., Opsahl, A., DeMarco, G., Boucher, M., Goodwin, B., Perreault, M., 2018. FGF21 increases water intake, urine output and blood pressure in rats. PloS one 13:e0202182.
Villarroya, J., Gallego-Escuredo, J.M., Delgado-Angles, A., Cairo, M., Moure, R., Gracia Mateo, M., Domingo, J.C., Domingo, P., Giralt, M., et al., 2018. Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue. Aging cell 17:e12822.
Wan, X.S., Lu, X.H., Xiao, Y.C., Lin, Y., Zhu, H., Ding, T., Yang, Y., Huang, Y., Zhang, Y., et al., 2014. ATF4- and CHOP-dependent induction of FGF21 through endoplasmic reticulum stress. Biomed Res Int 2014:807874.
Wang, W.F., Li, S.M., Ren, G.P., Zheng, W., Lu, Y.J., Yu, Y.H., Xu, W.J., Li, T.H., Zhou, L.H., et al., 2015. Recombinant murine fibroblast growth factor 21 ameliorates obesity-related inflammation in monosodium glutamate-induced obesity rats. Endocrine 49:119-29.
Woo, Y.C., Lee, C.H., Fong, C.H., Xu, A., Tso, A.W., Cheung, B.M., Lam, K.S., 2017. Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes. Clin Endocrinol 86:37-43.
Woo, Y.C., Xu, A., Wang, Y., Lam, K.S., 2013. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol 78:489-96.
Woods, J.A., Wilund, K.R., Martin, S.A., Kistler, B.M., 2012. Exercise, inflammation and aging. Aging Dis 3:130-40.
World Health Organization, 2020. WHO guidelines on physical activity and sedentary behaviour.
Wu, L., Qian, L., Zhang, L., Zhang, J., Zhou, J., Li, Y., Hou, X., Fang, Q., Li, H., et al., 2020. Fibroblast growth factor 21 is related to atherosclerosis independent of nonalcoholic fatty liver disease and predicts atherosclerotic cardiovascular events. J Am Heart Assoc e015226.
Wu, S., Grunwald, T., Kharitonenkov, A., Dam, J., Jockers, R., De Luca, F., 2013. Increased expression of fibroblast growth factor 21 (FGF21) during chronic undernutrition causes growth hormone insensitivity in chondrocytes by inducing leptin receptor overlapping transcript (LEPROT) and leptin receptor overlapping transcript-like 1 (LEPROTL1) expression. J Biol Chem 288:27375-83.
Wu, X., Qi, Y.F., Chang, J.R., Lu, W.W., Zhang, J.S., Wang, S.P., Cheng, S.J., Zhang, M., Fan, Q., et al., 2015. Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE(-/-) mice. Heart Vessels 30:657-68.
Xiao, Y., Xu, A., Law, L.S., Chen, C., Li, H., Li, X., Yang, L., Liu, S., Zhou, Z., et al., 2012. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab 97:E54-8.
Xie, T., Leung, P.S., 2017. Fibroblast growth factor 21: a regulator of metabolic disease and health span. Am J Physiol Endocrinol Metab 313:E292-e302.
Yan, H., Xia, M., Chang, X., Xu, Q., Bian, H., Zeng, M., Rao, S., Yao, X., Tu, Y., et al., 2011. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross- sectional study. PloS one 6:e24895.
Yang, S.J., Hong, H.C., Choi, H.Y., Yoo, H.J., Cho, G.J., Hwang, T.G., Baik, S.H., Choi, D.S., Kim, S.M., et al., 2011. Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol 75:464-9.
Yasunaga, A., Shibata, A., Ishii, K., Koohsari, M.J., Inoue, S., Sugiyama, T., Owen, N., Oka, K., 2017. Associations of sedentary behavior and physical activity with older adults' physical function: an isotemporal substitution approach. BMC Geriatr 17:280.
Yasunaga, A., Shibata, A., Ishii, K., Koohsari, M.J., Oka, K., 2018. Cross-sectional associations of sedentary behaviour and physical activity on depression in Japanese older adults: an isotemporal substitution approach. BMJ Open 8:e022282.
Yilmaz, Y., Eren, F., Yonal, O., Kurt, R., Aktas, B., Celikel, C.A., Ozdogan, O., Imeryuz, N., Kalayci, C., et al., 2010. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 40:887-92.
Yoo, H.J., Choi, K.M., 2015. Hepatokines as a Link between Obesity and Cardiovascular Diseases. Diabetes Metab J 39:10-5.
Zhang, C., Shao, M., Yang, H., Chen, L., Yu, L., Cong, W., Tian, H., Zhang, F., Cheng, P., et al., 2013. Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation. PloS one 8:e82275.
Zhang, X., Yeung, D.C., Karpisek, M., Stejskal, D., Zhou, Z.G., Liu, F., Wong, R.L., Chow, W.S., Tso, A.W., et al., 2008. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246-53.
Zhang, Y., Yan, J., Yang, N., Qian, Z., Nie, H., Yang, Z., Yan, D., Wei, X., Ruan, L., et al., 2021. High- Level Serum Fibroblast Growth Factor 21 Concentration Is Closely Associated With an Increased Risk of Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Front Cardiovasc Med 8:705273.
Zhao, C., Liu, Y., Xiao, J., Liu, L., Chen, S., Mohammadi, M., McClain, C.J., Li, X., Feng, W., 2015. FGF21 mediates alcohol-induced adipose tissue lipolysis by activation of systemic release of catecholamine in mice. J Lipid Res 56:1481-91.
Zhao, Y., Meng, C., Wang, Y., Huang, H., Liu, W., Zhang, J.F., Zhao, H., Feng, B., Leung, P.S., et al., 2016. IL-1beta inhibits beta-Klotho expression and FGF19 signaling in hepatocytes. Am J Physiol Endocrinol Metab 310:E289-300.
厚生労働省, 2017a. 平成 29 年患者調査.
厚生労働省, 2017b. 平成 30 年度 国民医療費.厚生労働省, 2020. 令和 2 年人口動態統計. 小西 守周, 中山 喜明, 増田 有紀, 2016. 細胞外分泌因子 FGF21 による生体機能調節. 生化学 88:86-93.
日本高血圧学会, 2019. 高血圧治療ガイドライン 2019.